A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

This double-blind, placebo-controlled Phase II trial (n=50) will investigate the effects of intravenous ketamine infusions on patients with depressive symptoms in the intensive care unit (ICU).

Conducted by Mayo Clinic, Florida, the study aims to evaluate the efficacy of ketamine hydrochloride compared to a placebo in treating depression. Participants, aged 18 to 99, must have been in the ICU for at least one week with a PHQ-9 score of 10 or higher and specific medical conditions. The trial will involve three consecutive days of either ketamine or placebo infusions, with assessments conducted at various intervals to measure changes in depressive symptoms.

The primary outcome measure is the change in depressive symptoms evaluated by the PHQ-9 scale. Recruitment for the study is not yet active, with an estimated study completion date of December 2024.

Topic Depression
Compound Ketamine Placebo
Country United States of America
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 December 2023
End date 31 December 2024
Phase Phase II
Design Blinded
Type Interventional
Generation First
Participants 50
Sex All
Age 18- 99
Therapy No

Trial Details

The purpose of this research is to study the effects of intravenous ketamine infusions for the treatment of patients with depressive symptoms in intensive care unit (ICU).

Trial Number NCT05803551

Sponsors & Collaborators

Mayo Clinic
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.